Kendall Powell - Medtronic PLC Lead Independent Director
| MDT Stock | USD 89.64 0.30 0.34% |
Director
Mr. Kendall J. Powell is Independent Director of the Company. Mr. Powell was Chairman of General Mills, Inc., an international producer, marketer and distributor of cereals, snacks and processed foods, since 2008 and was Chief Executive Officer of General Mills, Inc. from 2007 until June 2017. He was President and Chief Operating Officer of General Mills, Inc. from 2006 to 2007, and became a director of General Mills, Inc. in 2006. He was Executive Vice President and Chief Operating Officer, U.S. Retail from 2005 to 2006 and Executive Vice President of General Mills, Inc. from 2004 to 2005. From 1999 to 2004, Mr. Powell was Chief Executive Officer of Cereal Partners Worldwide, a joint venture of General Mills, Inc. and the Nestle Corporationrationration. Mr. Powell joined General Mills, Inc. in 1979. since 2015.
| Age | 66 |
| Tenure | 10 years |
| Address | Building Two, Galway, Ireland |
| Phone | 353 1 438 1700 |
| Web | https://www.medtronic.com |
Medtronic PLC Management Efficiency
The company has Return on Asset of 0.0441 % which means that on every $100 spent on assets, it made $0.0441 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0951 %, implying that it generated $0.0951 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.11 in 2025. Return On Capital Employed is likely to drop to 0.05 in 2025. Total Current Liabilities is likely to gain to about 13.5 B in 2025. Liabilities And Stockholders Equity is likely to gain to about 96.3 B in 2025Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Phebe Novakovic | Abbott Laboratories | 62 | |
| Nancy McKinstry | Abbott Laboratories | 62 | |
| Paul LaViolette | Edwards Lifesciences Corp | 63 | |
| Maria Hilado | Zimmer Biomet Holdings | 56 | |
| David Roux | Boston Scientific Corp | 67 | |
| Donna James | Boston Scientific Corp | 63 | |
| Michael Michelson | Zimmer Biomet Holdings | 69 | |
| Ronda Stryker | Stryker | 66 | |
| Ramona Sequeira | Edwards Lifesciences Corp | 55 | |
| Nelda Connors | Boston Scientific Corp | 55 | |
| Charles Dockendorff | Boston Scientific Corp | 66 | |
| Glenn Tilton | Abbott Laboratories | 72 | |
| Zachary CPA | Zimmer Biomet Holdings | N/A | |
| Sherilyn McCoy | Stryker | 62 | |
| Michelle Kumbier | Abbott Laboratories | 53 | |
| Mary Brainerd | Stryker | 67 | |
| William Link | Edwards Lifesciences Corp | 73 | |
| Robert Alpern | Abbott Laboratories | 70 | |
| Patricia Gonzalez | Abbott Laboratories | 49 | |
| Sally Blount | Abbott Laboratories | 59 | |
| Robert Hagemann | Zimmer Biomet Holdings | 64 | |
Management Performance
| Return On Equity | 0.0951 | ||||
| Return On Asset | 0.0441 |
Medtronic PLC Leadership Team
Elected by the shareholders, the Medtronic PLC's board of directors comprises two types of representatives: Medtronic PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medtronic. The board's role is to monitor Medtronic PLC's management team and ensure that shareholders' interests are well served. Medtronic PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medtronic PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brett Wall, Executive Vice President and President Restorative Therapies Group | ||
| Jennifer Kirk, Chief Accounting Officer, Global Controller | ||
| Bradley Lerman, Senior Vice President General Counsel, Corporate secretary | ||
| Scott Cundy, Senior Officer | ||
| Scott Donnelly, Lead Independent Director | ||
| Kenneth Washington, Senior Officer | ||
| Richard Anderson, Lead Independent Director | ||
| Ryan Weispfenning, Vice President - Investor Relations | ||
| Mark Ploof, Senior Services | ||
| Sean Lennon, Chief Officer | ||
| Hooman Hakami, Executive Vice President and Group President of the Medtronic Diabetes Group | ||
| Elizabeth Nabel, Independent Director | ||
| Richard Kuntz, Senior Vice President and Chief Scientific, Clinical and Regulatory Officer | ||
| James Lenehan, Independent Director | ||
| Mei Jiang, Senior Innovation | ||
| John Liddicoat, Executive Vice President and President Americas Region | ||
| Robert White, Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group | ||
| Kevin Lofton, Independent Director | ||
| Craig Arnold, Independent Director | ||
| Denise Blomquist, Global Officer | ||
| Kendall Powell, Lead Independent Director | ||
| Olaf Hedrich, Chief Officer | ||
| Sally Saba, Chief Inclusion and Diversity Officer | ||
| Denise OLeary, Independent Director | ||
| Omar Ishrak, Chairman of the Board, Chief Executive Officer | ||
| Brad Lerman, Senior Vice President General Counsel, Corporate secretary | ||
| Matt Walter, Chief Officer | ||
| Frank Chan, President Monitoring | ||
| Joon Hurh, VP Pacific | ||
| Torod Neptune, Senior Officer | ||
| Thierry Pieton, Chief Officer | ||
| Ivan Fong, General VP | ||
| Ivan JD, General VP | ||
| Sean Salmon, Executive Vice President and President, Diabetes Operating Unit, President, Cardiovascular Portfolio | ||
| Gary Corona, Senior Finance | ||
| Carol Surface, Chief Human Resource Officer, Senior Vice President | ||
| Karen Parkhill, Chief Financial Officer, Executive Vice President | ||
| Que Dallara, Executive Unit | ||
| Gregory Smith, Executive Operations | ||
| Michael Leavitt, Independent Director | ||
| Geoffrey Martha, Executive Vice President and President - Restorative Therapies Group | ||
| Robert Hopkins, Senior Strategy | ||
| Randall Hogan, Independent Director | ||
| Andrea Goldsmith, Independent Director | ||
| Robert Hoedt, Executive Vice President and President - EMEA Region | ||
| MSc MD, Medical Scientific | ||
| Michael Coyle, Executive Vice President, Group President - Cardiac and Vascular Group | ||
| MPH MD, Chief Business |
Medtronic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medtronic PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0951 | ||||
| Return On Asset | 0.0441 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 134.02 B | ||||
| Shares Outstanding | 1.28 B | ||||
| Shares Owned By Insiders | 0.27 % | ||||
| Shares Owned By Institutions | 86.89 % | ||||
| Number Of Shares Shorted | 13.07 M | ||||
| Price To Earning | 20.44 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Medtronic Stock Analysis
When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.